Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

(2018) Tiziano Barbui et al.   LEUKEMIA

Long-term treatment with interferon alfa for myeloproliferative neoplasms

(2017) Jean-Jacques Kiladjian   Lancet Haematology

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

(2017) Lucia Masarova et al.   Lancet Haematology

Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms

(2016) William Vainchenker et al.   BLOOD

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b

(2015) Nicole C.C. Them et al.   AMERICAN JOURNAL OF HEMATOLOGY

Myeloproliferative neoplasms: A decade of discoveries and treatment advances

(2015) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) A. M. Vannucchi et al.   ANNALS OF ONCOLOGY

Clinical and molecular response to interferon-  therapy in essential thrombocythemia patients with CALR mutations

(2015) E. Verger et al.   BLOOD

Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera

(2015) H. Gisslinger et al.   BLOOD

Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone

(2015) J-J Kiladjian et al.   LEUKEMIA

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-  in a murine model of polycythemia vera

(2013) A. Mullally et al.   BLOOD

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN 

(2013) S. Hasan et al.   BLOOD

Use of the 46/1 haplotype to model JAK2 V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment

(2013) S Hasan et al.   LEUKEMIA

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD